German Drug Delivery Specialist LTS Expands US Footprint with Renaissance Lakewood Acquisition

In a significant move that underscores the ongoing trend of pharmaceutical manufacturing investments in the United States, German pharmaceutical technology specialist LTS Lohmann has announced its acquisition of U.S. contract development and manufacturing organization (CDMO) Renaissance Lakewood. This strategic purchase, for an undisclosed sum, is set to bolster LTS's CDMO capabilities and strengthen its position in the global drug delivery solutions market.

Acquisition Details and Strategic Implications

LTS, known for its expertise in developing and manufacturing drug delivery systems, will add Renaissance's facility to its existing production sites in Germany, Israel, and the United States. The acquisition is expected to close by the end of November 2025, bringing approximately 500 employees into the LTS fold.

Renaissance Lakewood, founded in 1979 and headquartered in Lakewood, New Jersey, specializes in nasal sprays and sterile dosage forms. The company's impressive infrastructure includes over 310,000 square feet of manufacturing, laboratory, and support facilities across its New Jersey campus.

Bas van Buijtenen, LTS's chief executive, emphasized the strategic importance of the acquisition, stating, "This acquisition marks a significant step in our strategy to expand our CDMO capabilities and strengthen our position as a global leader in innovative drug delivery solutions. Renaissance's expertise in nasal sprays and sterile dosage forms perfectly complements our existing portfolio and will enable us to offer even greater value to our partners and patients worldwide."

US Manufacturing Expansion Trend

The LTS-Renaissance deal is part of a broader trend of pharmaceutical companies expanding their manufacturing presence in the United States. This movement has been partly fueled by concerns over potential pharmaceutical import tariffs, particularly under the Trump administration.

Recent examples of this trend include:

• OXB's acquisition of a commercial-scale drug factory in North Carolina from National Resilience for £3.4 million ($4.5 million).
• Spanish contractor Laboratorios Farmacéuticos Rovi's purchase of a production plant in Phoenix, Arizona, from Bristol Myers Squibb.
• Korea's Celltrion agreeing to pay 460 billion Korean won ($330 million) for an Eli Lilly drug substance plant in Branchburg, New Jersey.
• Ypsomed's plans to invest 200 million Swiss francs ($248 million) in building its first U.S. plant in Holly Springs, North Carolina.

These investments come in the wake of President Donald Trump's announcement in late September 2025, suggesting that companies may face a 100% import tariff on branded pharmaceutical products shipped from overseas unless they actively build production facilities in the U.S.

As the pharmaceutical industry continues to adapt to changing global dynamics and regulatory landscapes, acquisitions and expansions like LTS's purchase of Renaissance Lakewood are likely to play a crucial role in shaping the future of drug manufacturing and delivery.